Skip to content

Licorice and Home Blood Pressure

Licorice and Home Blood Pressure: a Randomized Crossover Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05661721
Enrollment
28
Registered
2022-12-22
Start date
2023-01-30
Completion date
2023-06-30
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension,Essential

Brief summary

Out-of-office blood pressure is more strongly associated with cardiovascular risk than office blood pressure. Licorice is known to raise blood pressure, but no previous studies have measured the effects on home blood pressure. The aim of this study is to analyze the association between licorice intake and home blood pressure.

Detailed description

Healthy volunteers will be invited to participate in a randomized, non-blinded, cross-over study. Participants will be randomized to either of two groups with a 1:1 allocation ratio, stratified by sex. Intervention will be sweet licorice and control will be salty licorice. A run-in period of 1 week will be followed by a 2-week intervention/control, a 2-week washout period, another 2-week control/intervention period and again a 2-week washout period. Home blood pressure will be measured continuously, and blood samples (including potassium and aldosterone) will be collected every two weeks. Analyses will be made comparing baseline characteristics of the two groups, intervention/control and washout period results of the two groups to look for potential carry-over effects, and finally comparing intervention and washout period results respectively to the baseline data to look for the effects of licorice.

Interventions

OTHERSweet licorice

Ecologic, vegan and gluten free, low-sodium sweet licorice pastilles made from Glycyrrhiza glabra, with a manufacturer specified content of 4% sugars, 2% glycyrrhizin and 0.03% salt, will be used as intervention. The exact glycyrrhizin content will be determined before the study begins, and participants will be instructed to consume a daily licorice dose that is equivalent to 100 mg of glycyrrhizin.

OTHERSalty licorice

A vegan and gluten free salty licorice without glycyrrhizin, flavored with ammonium chloride, with a manufacturer specified content of 0% sugars and 0.05% salt, will be used as control. The amount of salty licorice will be the same as for sweet licorice, and thus determined after the glycyrrhizin content analysis of the sweet licorice.

Sponsors

Linkoeping University
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18 to 30 years

Exclusion criteria

* known hypertension, cardiovascular disease, kidney disease, liver disease, hormonal disease, peanut allergy, eating disorder or headache disease (including tension headache and migraine) * known alcohol abuse or drug abuse (including cannabis and anabolic steroids) * treatment with hormonal drugs (including oral contraceptives * known intolerance to licorice intake

Design outcomes

Primary

MeasureTime frameDescription
Systolic home blood pressure (mmHg)Mean at the end of 14 days of intervention compared with mean during run-in periodSystolic home blood pressure (mmHg)
Diastolic home blood pressure (mmHg)Mean at the end of 14 days of intervention compared with mean during run-in periodDiastolic home blood pressure (mmHg)

Secondary

MeasureTime frameDescription
Plasma sodium (mmol/L)Mean at the end of 14 days of intervention compared with mean during run-in periodPlasma sodium (mmol/L)
Body weight (kg)Mean at the end of 14 days of intervention compared with mean during run-in periodBody weight (kg)
Serum aldosterone (μmol/L)Mean at the end of 14 days of intervention compared with mean during run-in periodSerum aldosterone (μmol/L)
Plasma renin (mIU/L)Mean at the end of 14 days of intervention compared with mean during run-in periodPlasma renin (mIU/L)
Plasma potassium (mmol/L)Mean at the end of 14 days of intervention compared with mean during run-in periodPlasma potassium (mmol/L)

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026